A detailed history of Platinum Investment Management LTD transactions in Inhibrx, Inc. stock. As of the latest transaction made, Platinum Investment Management LTD holds 145,966 shares of INBX stock, worth $2.07 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
145,966
Previous 167,763 12.99%
Holding current value
$2.07 Million
Previous $6.37 Million 19.96%
% of portfolio
0.21%
Previous 0.27%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$32.76 - $39.56 $714,069 - $862,289
-21,797 Reduced 12.99%
145,966 $5.1 Million
Q4 2023

Feb 13, 2024

SELL
$14.5 - $38.0 $888,458 - $2.33 Million
-61,273 Reduced 26.75%
167,763 $6.37 Million
Q2 2023

Aug 10, 2023

BUY
$16.96 - $27.82 $115,785 - $189,927
6,827 Added 3.07%
229,036 $5.95 Million
Q1 2023

May 11, 2023

BUY
$18.45 - $27.14 $1.15 Million - $1.68 Million
62,082 Added 38.77%
222,209 $4.19 Million
Q4 2022

Feb 13, 2023

BUY
$20.18 - $33.33 $280,845 - $463,853
13,917 Added 9.52%
160,127 $3.95 Million
Q3 2022

Nov 14, 2022

SELL
$11.58 - $24.73 $160,834 - $343,474
-13,889 Reduced 8.68%
146,210 $2.62 Million
Q2 2022

Aug 11, 2022

BUY
$8.52 - $25.26 $623,408 - $1.85 Million
73,170 Added 84.17%
160,099 $1.82 Million
Q4 2021

Feb 11, 2022

SELL
$26.75 - $46.02 $445,494 - $766,417
-16,654 Reduced 16.08%
86,929 $3.8 Million
Q3 2021

Nov 09, 2021

SELL
$25.18 - $37.81 $1.3 Million - $1.96 Million
-51,818 Reduced 33.34%
103,583 $3.45 Million
Q1 2021

May 13, 2021

BUY
$16.27 - $41.26 $1.55 Million - $3.93 Million
95,296 Added 158.55%
155,401 $3.12 Million
Q4 2020

Feb 12, 2021

SELL
$15.96 - $50.0 $237,724 - $744,750
-14,895 Reduced 19.86%
60,105 $1.98 Million
Q3 2020

Nov 13, 2020

BUY
$16.77 - $20.65 $1.26 Million - $1.55 Million
75,000 New
75,000 $1.35 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Platinum Investment Management LTD Portfolio

Follow Platinum Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Platinum Investment Management LTD with notifications on news.